Navigation Links
Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Date:9/21/2007

which may enhance efficacy when used as a postexposure prophylaxis for preventing pneumonic tularemia among individuals exposed to aerosolized Francisella tularensis. Thus, cethromycin appears promising as a therapy for tularemia infections.

The FDA has not approved cethromycin as a treatment for CAP or any other indication.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and inflammation. The Company's lead candidate, cethromycin, is a novel once-a-day antibiotic in late-stage clinical development for the treatment of respiratory tract infections including CAP. For more information, please visit us on the web at http://www.advancedlifesciences.com.

About Cethromycin

Advanced Life Sciences is developing cethromycin, a novel once-a-day antibiotic in response to the emerging bacterial resistance observed in the treatment of community acquired pneumonia (CAP). Cethromycin has been tested in approximately 5,000 human subjects during clinical trials.

The Company has conducted two, pivotal Phase III clinical trials of cethromycin for the treatment of mild-to-moderate CAP. In June of 2007, Advanced Life Sciences released positive results from the first of these two trials, Trial CL-06, which showed that cethromycin met primary and secondary clinical endpoints. Data from the second CAP pivotal trial is expected to be reported in the Fall. The Company believes that cethromycin, if approved, would build upon the growing market opportunity in the antibiotic marketplace and address the critical need for antibiotics that overcome bacterial resistance.

Forward-Looking Statements

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements within the
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
3. Phase III Clinical Trial with 4-Month Long-Acting Formulation of Triptorelin: Ipsen Decides Not to Perform Further Administration
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
6. Liponex Inc. Reports Further Analysis of CRD5 Phase I/II Clinical Trial Data
7. MIV Therapeutics Announces Pivotal Test Results Further Validating Company Stent Coatings Meet Critical FDA Fatigue Guidelines
8. Managing Preanalytical Processes for Patient Safety
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
11. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)... , NEW YORK, Nov. 30 Report...port is available in its catalogue: ,, Surgica.../www.reportlinker.com/p0164299/Surgical-Incision-C...ion closures market holds enormous significance, d...rformed each year. Surgical disciplines such as ca...
(Date:11/30/2009)..., KING OF PRUSSIA, Pa., Nov. 30 ... completion of a Phase I study of CPSI-2364, its o...uction of TNF-alpha and other pro-inflammatory cyt...se escalation study in healthy volunteers confirm ...sting. ,, All 30 enrolled subjects completed ...
(Date:11/30/2009)..., CHICAGO, Nov. 30 MedPro Imagi...asound solutions, will showcase leading ultrasound...iq I and Siemens X300 Premium Edition during the c...rth America (RSNA) conference, being held in Chica... MedPro Imaging markets ultrasound products and se...
Breaking Medicine Technology:Reportlinker Adds Surgical Incision Closures - Global Trends 2Reportlinker Adds Surgical Incision Closures - Global Trends 3Reportlinker Adds Surgical Incision Closures - Global Trends 4Reportlinker Adds Surgical Incision Closures - Global Trends 5Reportlinker Adds Surgical Incision Closures - Global Trends 6Reportlinker Adds Surgical Incision Closures - Global Trends 7Cytokine PharmaSciences Completes Phase I Study of Oral Anti-Inflammatory Agent, CPSI-2364 2MedPro Imaging to Showcase Leading New and Refurbished Ultrasound Solutions at RSNA 2Relators Attorneys Comment On AtriCure DOJ Proposed Settlement 5996 1Relators Attorneys Comment On AtriCure DOJ Proposed Settlement 5996 2USGS science picks 10641 1USGS science picks 10641 2USGS science picks 10641 3USGS science picks 10641 4USGS science picks 10641 5USGS science picks 10641 6USGS science picks 10641 7TV bombards children with commercials for high fat and high sugar foods 10639 1TV bombards children with commercials for high fat and high sugar foods 10639 2TV bombards children with commercials for high fat and high sugar foods 10639 3
...YORK, May 16 Pulmo BioTech Inc. (OTC,Bulletin Boa...ogy and,purpose of its Phase I Human Trials with i...diagnosis of Pulmonary Embolism and Pulmonary,Hype...lmo BioTech subsidiary,PulmoScience Inc., and the ... PulmoBind for Molecular Imaging of the Pulmonary ...
...GEWATER, N.J., May 16 Data from three studies,eva...emoglobin (Hb) levels,and the rate of blood transf...ions on reimbursement for erythropoiesis-stimulati...n,s blood supply, will be presented at the,America...ng later this,month. The meeting will take place i...
Other Medicine Technology:Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials 2Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials 3New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 3New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 4New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 5New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 6
(Date:11/30/2009)...aunched a series of clinical trials in order to as...his approach involves the application of personali...s from the patient him or herself and designed to ...nd frequent malignant tumours. The new therapy is ...th the standard, first-line treatment involving su...
(Date:11/30/2009)...do knees, internal injuries, study finds, , ...re a middle-age weekend warrior who likes to hit t...ew study suggests that high levels of physical act...could lead to osteoarthritis. , The study found...ho showed no symptoms and had a healthy weight. Th...
(Date:11/30/2009)...giving catalog to help families make charitable gi... 30 In spite of the eco...y season willing to support charities in two ways,...wn wallets to support charities and nearly 40 perc...instead of buying them a gift, according to a new ...
(Date:11/30/2009)...ewswire-FirstCall/ -- Stryker Corporation (NYSE: ...acquire privately held Ascent Healthcare Solutions...emanufacturing of medical devices in the U.S. ,...acquire Ascent Healthcare Solutions for $525 milli...itioned on the expiration or termination of all ap...
(Date:11/30/2009)...k up , , MONDAY, Nov. 30 (HealthDay News...e U.S. Congress differ in a number of ways but ach...mber of uninsured Americans. , Legislation appr...month would expand coverage to 96 percent of Ameri... to expand coverage to 94 percent of Americans. ,...
Breaking Medicine News(10 mins):Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 2Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 3Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 4Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 5Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 6Health News:Lots of Exercise in Midlife May Lead to Osteoarthritis 2Health News:Lots of Exercise in Midlife May Lead to Osteoarthritis 3Health News:American Red Cross Survey Finds 62 Percent of Americans Plan to Donate More Than $25 to Charity This Holiday Season in Spite of Economic Downturn 2Health News:American Red Cross Survey Finds 62 Percent of Americans Plan to Donate More Than $25 to Charity This Holiday Season in Spite of Economic Downturn 3Health News:Stryker Announces Definitive Agreement To Acquire Ascent Healthcare Solutions 2Health News:Stryker Announces Definitive Agreement To Acquire Ascent Healthcare Solutions 3Health News:Health Reform: What's in It for You? 2Health News:Health Reform: What's in It for You? 3
...enefits of Frameless Delivery and Fractionation De... Preservation , , SUNNYVALE, Calif., May 5 Accur... in the field of radiosurgery, announced today tha...ion of Neurological Surgeons (AANS) Annual Meeting...
...nline and Phone Based Survey Encourages Nurses to ...areers , , , PORTLAND, Ore., May 5 Vigilan, the...brates National Nurse Week May 6-12, 2009 by liste...ementia care. Vigilan is offering an online and p...
...ONDON, May 5 Initiatives taken by European govern...ion surveillance systems have aimed at improving e...r, the lack of basic level automation is proving t...ts across Europe to install infection surveillance...
...ADISON HEIGHTS, Mich., May 5 InfuSystem Holdings... the leading provider of ambulatory infusion pumps... financial results and provided a business update ...e first quarter of 2009, despite a nationwide shor...
...irst Diagnostic Test for Identifying E. coli, K. p... Blood Cultures , , PNA FISH Provides Critical Re... to Help Clinicians Improve Care and Outcomes for ...0(k) clearance for EK/ P. aeruginosa PNA FISH(R) ...
... , , REDWOOD CITY, Calif., May 5 Ingenuity Syste...for life science researchers, today announced a mu...plans to expand the utilization of IPA in its rese... researchers plan to leverage the powerful analysi...
Other Medicine News:Health News:Presentations at Leading Neurosurgery Meeting Highlight Benefits of CyberKnife Radiosurgery for the Treatment of CNS Indications 2Health News:Presentations at Leading Neurosurgery Meeting Highlight Benefits of CyberKnife Radiosurgery for the Treatment of CNS Indications 3Health News:Presentations at Leading Neurosurgery Meeting Highlight Benefits of CyberKnife Radiosurgery for the Treatment of CNS Indications 4Health News:Presentations at Leading Neurosurgery Meeting Highlight Benefits of CyberKnife Radiosurgery for the Treatment of CNS Indications 5Health News:Vigilan Honors National Nurse Week in Assisted Living, Independent Living and Dementia Care 2Health News:Frost & Sullivan: Rising Public Awareness Promoting Acceptance of Infection Surveillance Systems Across Europe 2Health News:Frost & Sullivan: Rising Public Awareness Promoting Acceptance of Infection Surveillance Systems Across Europe 3Health News:InfuSystem Holdings Reports $9.2 Million of Revenue and 45% Increase in Adjusted EBITDA for the First Quarter of 2009 2Health News:InfuSystem Holdings Reports $9.2 Million of Revenue and 45% Increase in Adjusted EBITDA for the First Quarter of 2009 3Health News:InfuSystem Holdings Reports $9.2 Million of Revenue and 45% Increase in Adjusted EBITDA for the First Quarter of 2009 4Health News:InfuSystem Holdings Reports $9.2 Million of Revenue and 45% Increase in Adjusted EBITDA for the First Quarter of 2009 5Health News:InfuSystem Holdings Reports $9.2 Million of Revenue and 45% Increase in Adjusted EBITDA for the First Quarter of 2009 6Health News:InfuSystem Holdings Reports $9.2 Million of Revenue and 45% Increase in Adjusted EBITDA for the First Quarter of 2009 7Health News:AdvanDx Receives FDA 510(k) Clearance for EK/P. aeruginosa PNA FISH(R) 2Health News:AdvanDx Receives FDA 510(k) Clearance for EK/P. aeruginosa PNA FISH(R) 3Health News:Ingenuity Systems Announces Multi-Year Deal With AstraZeneca 2Health News:Ingenuity Systems Announces Multi-Year Deal With AstraZeneca 3
Revo Rotator Cuff Repair System
BioROC EZ Fasteners and Instrumentation
...a fully absorbable soft tissue anchor designed spe...s dynamic engagement into cancellous bone, its bro...de significant resistance to pullout in soft bone....ction provides the benefits of fixation strength c...
...ade; Ti Quick-T Fixation System is a single-step t...r secondary tissue fixation. This through tendon t...e Anchor combined with our pretied knot technology...e of PEEK-OPTIMA® LT3 polymer from Invibio. Th...
Medicine Products: